Iradimed Reports Record Q3 Revenue of $24.2 Million, Raises Dividend

What happened

Iradimed reported record third-quarter 2026 revenue of $24.2 million, up 14% from a year earlier, with diluted GAAP earnings per share of $0.51. The company also declared a quarterly dividend of $0.20 per share and raised its full-year 2026 revenue outlook.

Confirmed

Global impact / market context

Faster revenue growth alongside a higher dividend signals the company is generating more cash than it needs for daily operations, which can support investor returns. A rising full-year outlook suggests management expects demand for its medical devices to stay strong through year-end.

Analyst inference

Record bookings, especially a 45% jump in domestic pump-channel bookings, point to future sales being locked in before they are billed as revenue. That order backlog gives more visibility into coming quarters than the reported revenue alone.

Analyst inference

What to watch

1. Fourth-quarter revenue is expected to be $25.0 million to $26.5 million, and the revised full-year 2026 outlook is $91.6 million to $93.1 million, so actual results can be compared with these figures. Confirmed
2. Watch whether the record bookings convert into reported revenue in coming quarters, and whether more than 70% of pump bookings staying in the quad-stack setup holds. Proposed
3. Gross margin fell to 76% from 78% a year earlier, so investors should track whether this profit-per-sale decline continues as revenue grows and costs change. Analyst inference

Evidence

• Original source link unavailable